Searched for
PFIZER ADJUSTED EPS
US stock market crashes today: Why Nasdaq, S&P 500 and Dow Jones all turned red – Gold and silver surge as investors rotate into safetyUS stock market crashes today: Nasdaq, S&P 500, Dow fall as gold and silver rally on investor fear. The Nasdaq Composite plunged 1.01% to 2...- Why is PFE stock falling today despite beating Pfizer's earnings estimates? Key factors investors are watchingPFE stock today: Pfizer's stock dipped despite strong fourth-quarter earnings. Investors reacted to the company's modest 2026 outlook. Decl...
- PFE stock rises 5.3% today: Pfizer seals Trump drug price deal with $70 billion U.S. investment and $7.3 billion Metsera weight-loss acquisitionPfizer Inc. (NYSE: PFE) experienced a significant uptick in its stock price following two major announcements on September 30, 2025. Presid...
- Pfizer stock soars as earnings smash expectations, and company raises outlookPFE stock: Pfizer's stock surged following a report of stronger-than-expected earnings, driven by robust sales of COVID-19 products and key...
- Pfizer exceeds Q4 earnings estimates as covid product sales outperform expectationsStrong Covid product sales and cost-cutting initiatives drove Pfizer's $17.76 billion in revenue in Q4, exceeding Wall Street's projections...
- Windlas Biotech offers its shares at 64x PE. Should you subscribe?The Dehradun-based firm will raise Rs 165 crore through issuance of fresh equity shares, while the promoters and existing shareholders will...
- Buy Pfizer, target price Rs 4,705: ICICI SecuritiesThe brokerage believes that the difference between primary and secondary sales would normalise in the coming quarters. However, revenue wou...
- 10 stocks that saw target price revision, re-rating post Q2 nosBrokerage Sharekhan said Sensex companies posted 8.1 per cent year-on-year profit growth.
- Pfizer surges 5% as parent acquires Medivation in $14 bn dealThe US-based company said the acquisition would be immediately accretive to adjusted diluted EPS upon closing of the deal.
- GlaxoSmithKline's CEO Andrew Witty backs India's pharma policy, cautious on acquisitions"I think it is wholly reasonable for a country that is having a tremendous growth with challenges has to think about pricing," Witty said.
- Pfizer 4Q profit beats views as revenue up 6 pcPfizer Inc.'s new CEO on Tuesday outlined plans to reduce the company's spending and work force and focus more sharply on promising drugs a...
- Edelweiss Securities puts 'buy' on Aurobindo PharmaRevenues are expected to grow at a CAGR of 20% over FY09-11E to Rs 4,400 crore, backed by high growth in the US formulations sales and pote...
Load More
